Intranasal Epinephrine (NS-002)
Access to Epinephrine is a priority for reducing Anaphylaxis. Intranasal Epinephrine aimed at assisting in acute emergency situations.
Medical need
Definition: Severe allergic type 1 reaction. Life threatening.
Prevalence: 1.5 % of the US population suffer an event each
(500,000 cases annually)
Cost of treatment 4 B annually
Mortality rates 1.2 % per episode, 30 % recurrence risk lifetime
Epinephrine IM or IV is the first line treatment.
Nasus Pharma presented clinical results of intranasal epinephrine in EAACI, July 2022, Prague
